Table 1.
Clinical characteristics of six infants with KMT2A-rearranged acute lymphoblastic leukemia and corresponding cell lines.
| Patient ID | Sex | Age (days) at diagnosis | WBC at presentation (×109/L) | CNS status at diagnosis | Upfront therapy | Relapse | Time (months) from diagnosis to relapse | Relapse therapy | Outcome | Corresponding cell line* |
|---|---|---|---|---|---|---|---|---|---|---|
| P272 | Female | 336 | 317.0 | CNS1 | CCG 1883 | BM | 3 | CCG 1008 | Died of Disease; OS 5 months |
PER-494 PER-485 (Relapse) |
| P287 | Female | 9 | 111.8 | CNS2 | CCG 1883 | BM | 3 | CCG 0922 | Died of Disease; OS 4 months |
PER-490 |
| P337 | Female | 82 | 564.0 | CNS2 | CCG 1901 → HSCT | BM | 16 | CCG 1882 → HSCT2 | Alive without disease; 26 years of age at last follow-up |
PER-784 PER-826 |
| P399 | Female | 66 | 670.0 | CNS1 | CCG 1953 | No | _ | _ | Alive without disease; 24 years of age at last follow-up | PER-785 |
| P810 | Female | 52 | 102.0 | CNS2 | COG P9407 → HSCT | No | _ | _ | Died from hepatic sinusoidal obstruction syndrome post HSCT; OS 4 months | PER-703 |
| P899 | Male | 365 | 156.6 | CNS1 | COG AALL0631 | No | _ | _ | Alive without disease; 6 years of age at last follow-up |
PER-910 |
*All cell lines were derived at diagnosis except for PER-485 which was derived at first relapse.
BM, Bone Marrow; CCG, Children’s Cancer Group; COG, Children’s Oncology Group; CNS, Central Nervous System; OS, Overall Survival; WBC, White Blood Cell.